Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

February 22, 2021August 24, 2022

Enhertu Approved in UK for Inoperable, Advanced Breast Cancer

News

Enhertu (trastuzumab deruxtecan) has been granted conditional approval in the U.K. for the treatment of adults with inoperable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based ... Read more

January 7, 2021January 7, 2021

ARX788 on FDA Fast Track for Advanced HER2-positive Breast Cancers

News

ARX788 has been given a fast track designation by the U.S. Food and Drug Administration as a monotherapy for patients with HER2-positive metastatic breast cancer previously treated with at least ... Read more

January 4, 2021January 4, 2021

Conditional Approval Urged in EU for Trastuzumab Deruxtecan

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended the conditional approval of trastuzumab deruxtecan (DS-8201) for the treatment of patients with inoperable or metastatic HER2-positive breast ... Read more

December 17, 2020December 17, 2020

Antibody-drug Combo Shows Early Promise in Targeting Cancers, Company Says

News

BrickBio’s antibody-drug conjugate BRKB-28 showed preclinical effectiveness in eradicating breast cancer cells while leaving healthy cells unharmed, the company announced. BRKB-28 combines an antibody against a cancer protein with a ... Read more

December 7, 2020December 7, 2020

Onconova Seeking FDA Approval for Phase 1 Trial of ON 123300 for Breast Cancer

News

Onconova Therapeutics is seeking the green light from the U.S. Food and Drug Administration (FDA) to begin a Phase 1 clinical trial for its small molecule ON 123300 in certain ... Read more

November 30, 2020November 30, 2020

FDA Gives Breakthrough Device Status to 4D Path’s Breast Cancer Diagnostic Platform

News

The U.S. Food and Drug Administration (FDA) has designated 4D Path’s software a breakthrough device as a possible way to achieve a faster and more accurate breast cancer diagnosis based on tissue taken ... Read more

November 2, 2020November 2, 2020

FDA Approves FoundationOne Liquid CDx as Companion Diagnostic Test for Piqray Treatment

News

The U.S. Food and Drug Administration (FDA) has expanded the approval of Foundation Medicine’s FoundationOne Liquid CDx as a companion diagnostic test for identifying advanced or metastatic breast cancer patients suitable for treatment ... Read more

October 19, 2020October 19, 2020

Signatera Test for Residual Disease Will Be Used in New Phase 2 Breast Cancer Trial

News

Signatera, Natera’s personalized test to detect residual signs of cancer in people with solid tumors, will be used in an upcoming Phase 2 trial as a tool to identify patients with ... Read more

June 22, 2020June 22, 2020

Pre-Surgical Imfinzi Combo Increases Cancer Eradication Chances in Trial

News

Treating high-risk, HER2-negative breast cancer patients before surgery with the immunotherapy Imfinzi (durvalumab) plus Lynparza (olaparib) and chemotherapy increases the probability for complete cancer eradication, according to the results from a Phase ... Read more

April 23, 2020April 23, 2020

Trodelvy Approved for Heavily Pre-treated TNBC Patients in US

News

The U.S. Food and Drug Administration (FDA) has approved Immunomedics’ antibody-drug conjugate Trodelvy (sacituzumab govitecan) to treat triple-negative breast cancer (TNBC) patients who already tried at least two previous therapies for metastatic disease. ... Read more